Focus-X

Focus-X is a company that develops targeted radiopharmaceuticals for cancer treatment based on its proprietary peptide engineering technology. Focus-X has developed a proprietary engineering platform primarily dedicated to creating peptide radioligands that precisely deliver alpha or beta radionuclides to break down cancer cell DNA. The platform enables high-quality optimization of peptide radioligand carriers for key drug attributes such as biodistribution, binding affinity, and in vivo stability, which presents a significant challenge for other ligand-targeting compounds like antibodies.